# OnCo record hcc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/hcc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "hcc" ;
  schema:name "Hepatocellular carcinoma"@en ;
  schema:alternateName "LIHC"@en, "TCGA-LIHC"@en, "liver hepatocellular carcinoma (TCGA LIHC cohort)"@en, "Liver Cancer"@en ;
  schema:description "Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."@en ;
  schema:url <https://onco.cc/cancers/hcc/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hepatocellular_carcinoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1148337> ;
  schema:citation <https://en.wikipedia.org/wiki/Hepatocellular_carcinoma> ;
  onco:tag "gi", "spike" ;
  onco:related <https://onco.cc/pairings/io-plus-vegf/>, <https://onco.cc/pairings/tace-plus-systemic/>, <https://onco.cc/pairings/io-varices-caution/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/hifu-histotripsy/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/hpv-vaccine/>, <https://onco.cc/technologies/tace/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/technologies/liver-transplant-oncology/>, <https://onco.cc/technologies/hcc-surveillance/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/sbrt/> ;
  onco:targets <https://onco.cc/targets/gpc3/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/fap/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/met/> ;
  onco:companies <https://onco.cc/companies/nanjing-leads-biolabs/>, <https://onco.cc/companies/catalym/>, <https://onco.cc/companies/bioinvent-international/>, <https://onco.cc/companies/ascentawits-pharmaceuticals/>, <https://onco.cc/companies/shanghai-abelzeta/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/eisai/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/exelixis/>, <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/hengrui/>, <https://onco.cc/companies/elevar-therapeutics/>, <https://onco.cc/companies/sirtex/>, <https://onco.cc/companies/boston-scientific/> ;
  onco:institutions <https://onco.cc/institutions/asan-medical-center/>, <https://onco.cc/institutions/mayo-clinic/>, <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/sysucc/>, <https://onco.cc/institutions/snuh/>, <https://onco.cc/institutions/gustave-roussy/> ;
  onco:pathways <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/hepatocellular-carcinoma-signalling/> ;
  onco:terms <https://onco.cc/terms/afp/>, <https://onco.cc/terms/child-pugh-albi/>, <https://onco.cc/terms/bclc-staging/>, <https://onco.cc/terms/hbv-hcv/>, <https://onco.cc/terms/dosimetry/>, <https://onco.cc/terms/tace-term/> ;
  onco:trials <https://onco.cc/trials/nct06109272/>, <https://onco.cc/trials/nct05317819/>, <https://onco.cc/trials/nct07490262/>, <https://onco.cc/trials/nct06844357/>, <https://onco.cc/trials/nct04639180/>, <https://onco.cc/trials/nct05320692/>, <https://onco.cc/trials/nct04194775/>, <https://onco.cc/trials/nct03755791/>, <https://onco.cc/trials/nct05489289/>, <https://onco.cc/trials/nct06921785/>, <https://onco.cc/trials/nct05862337/>, <https://onco.cc/trials/nct05883644/>, <https://onco.cc/trials/nct03847428/>, <https://onco.cc/trials/nct05904886/>, <https://onco.cc/trials/nct03383458/>, <https://onco.cc/trials/nct05557838/>, <https://onco.cc/trials/nct06371157/>, <https://onco.cc/trials/nct04712643/>, <https://onco.cc/trials/nct05201404/> ;
  onco:people <https://onco.cc/people/audre-lorde/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-alcohol-cancer-burden-lancet-oncol-2021/> ;
  onco:journals <https://onco.cc/journals/journal-of-gastrointestinal-cancer/> ;
  onco:pipeline <https://onco.cc/technologies/fapi-pet/>, <https://onco.cc/drugs/pf-08634404/>, <https://onco.cc/drugs/budigalimab/>, <https://onco.cc/drugs/livmoniplimab/>, <https://onco.cc/drugs/cobolimab/>, <https://onco.cc/drugs/adi-peg20/>, <https://onco.cc/drugs/ibi310/>, <https://onco.cc/drugs/adg126/>, <https://onco.cc/drugs/azd9793/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/drugs/camrelizumab-rivoceranib/>, <https://onco.cc/trials/emerald-3/>, <https://onco.cc/pairings/tace-plus-systemic/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/targets/gpc3/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/ideas/idea-hcc-io-before-transplant/>, <https://onco.cc/ideas/idea-hcc-blood-surveillance/>, <https://onco.cc/technologies/hcc-surveillance/>, <https://onco.cc/technologies/mced/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/technologies/hifu-histotripsy/>, <https://onco.cc/drugs/ivonescimab/> ;
  onco:standardOfCare <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/hifu-histotripsy/>, <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/terms/hbv-hcv/>, <https://onco.cc/technologies/hpv-vaccine/>, <https://onco.cc/technologies/hcc-surveillance/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/terms/afp/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/liver-transplant-oncology/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/terms/bclc-staging/>, <https://onco.cc/technologies/tace/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/trials/emerald-1/>, <https://onco.cc/trials/leap-012/>, <https://onco.cc/trials/emerald-3/>, <https://onco.cc/trials/imbrave150/>, <https://onco.cc/trials/himalaya/>, <https://onco.cc/trials/checkmate-9dw/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/trials/resorce/>, <https://onco.cc/trials/celestial/>, <https://onco.cc/trials/imbrave050/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/technologies/sbrt/> .